SINGAPORE -- UK-headquartered Glympse Bio has raised $46.7 million in an oversubscribed series B funding round from a slew of investors, including Singapore state-owned investment company Temasek.
The investment from Temasek marks a continuation of the fund's interest in biotechnology investments.
